Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 4/2019

01-10-2019 | Gastric Cancer | Review Article

Nanoparticle albumin-bound paclitaxel: a big nano for the treatment of gastric cancer

Authors: G. Roviello, F. U. Conter, E. Mini, D. Generali, M. Traversini, D. Lavacchi, S. Nobili, N. Sobhani

Published in: Cancer Chemotherapy and Pharmacology | Issue 4/2019

Login to get access

Abstract

Gastric cancer (GC) is the third cause of cancer-related death worldwide. Patients with unresectable GC can be treated with chemotherapy such as paclitaxel, which is a microtubule stabilizer. The use of nanoparticle albumin-bound paclitaxel (nab-ptx) avoids hypersensitivity reactions due to the absence of solvent needed to dissolve paclitaxel and it can be administered at higher doses. The ABSOLUTE randomized phase-3 clinical trial showed the non-inferiority of the nab-ptx used every week compared to the solvent-based paclitaxel used every week. This review describes the current advancements of the use of nab-ptx in GC in preclinical and clinical study investigations. The possibility of combining nab-ptx with other medications to improve response of patients to their specific molecular needs will also be debated.
Literature
1.
Bray F et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424CrossRef
2.
Yokoyama T (2011) Clinicopathological analysis for recurrence of stage Ib gastric cancer (according to the second English edition of the Japanese classification of gastric carcinoma). Gastric Cancer 14:372–377CrossRef
3.
Ilson DH (2018) Advances in the treatment of gastric cancer. Curr Opin Gastroenterol 34:465–468CrossRef
4.
Petrioli R, Roviello G, Zanotti L, Roviello F, Polom K, Bottini A, Marano L, Francini E, Marrelli D, Generali D (2016) Epirubicin-based compared with docetaxel-based chemotherapy for advanced gastric carcinoma: A systematic review and meta-analysis. Crit Rev Oncol Hematol 102:82–88CrossRef
5.
Petrioli R et al (2015) Sequential treatment with epirubicin, oxaliplatin and 5FU (EOF) followed by docetaxel, oxaliplatin and 5FU (DOF) in patients with advanced gastric or gastroesophageal cancer: a single-institution experience. Cancer Chemother Pharmacol 75(5):941–947CrossRef
6.
Ford HER et al (2014) Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol 15:78–86CrossRef
7.
Kang JH et al (2012) Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol 30:1513–1518CrossRef
8.
Thuss-Patience PC et al (2011) Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer–a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer 47:2306–2314CrossRef
9.
Wilke H, Muro K, Van Cutsem E et al (2014) Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 15(11):1224–1235CrossRef
10.
Kang JH, Lee SI, do Lim H et al (2012) Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol 30:1513–1518CrossRef
11.
Roviello G, Ravelli A, Fiaschi AI et al (2016) Apatinib for the treatment of gastric cancer. Expert Rev Gastroenterol Hepatol 10(8):887–892PubMed
12.
Kang YK, Boku N, Satoh T et al (2017) Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390(10111):2461–2471CrossRef
13.
Shitara K, Doigf T, Dvorkin M et al (2018) Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 19(11):1437–1448CrossRef
14.
Gelderblom H, Verweij J, Nooter K, Sparreboom A (2001) Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 37:1590–1598CrossRef
15.
Dorr RT (1994) Pharmacology and toxicology of Cremophor EL diluent. Ann Pharmacother 28:S11–S14CrossRef
16.
Ibrahim NK et al (2002) Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 8:1038–1044PubMed
17.
Nyman DW et al (2005) Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J Clin Oncol 23:7785–7793CrossRef
18.
Schneeweiss A, Seitz J, Smetanay K, Schuetz F, Jaeger D, Bachinger A, Zorn M, Sinn HP, Marmé F (2014) Efficacy of nab-paclitaxel does not seem to be associated with SPARC expression in metastatic breast cancer. Anticancer Res 34(11):6609–6615PubMed
19.
Hidalgo M, Plaza C, Musteanu M, Illei P, Brachmann CB, Heise C, Pierce D, Lopez-Casas PP, Menendez C, Tabernero J, Romano A, Wei X, Lopez-Rios F, Von Hoff DD (2015) SPARC expression did not predict efficacy of nab-paclitaxel plus gemcitabine or gemcitabine alone for metastatic pancreatic cancer in an exploratory analysis of the phase III MPACT trial. Clin Cancer Res 21(21):4811–4818CrossRef
20.
Schettini F, Giuliano M, De Placido S, Arpino G (2016) Nab-paclitaxel for the treatment of triple-negative breast cancer: rationale, clinical data and future perspectives. Cancer Treat Rev 50:129–141CrossRef
21.
Desai N et al (2006) Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 12:1317–1324CrossRef
22.
Gardner ER et al (2008) Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel. Clin Cancer Res 14:4200–4205CrossRef
23.
Zhang C, Awasthi N, Schwarz MA, Hinz S, Schwarz RE (2013) Superior antitumor activity of nanoparticle albumin-bound paclitaxel in experimental gastric cancer. PLoS One 8:e58037CrossRef
24.
Kinoshita J et al (2014) Comparative study of the antitumor activity of nab-paclitaxel and intraperitoneal solvent-based paclitaxel regarding peritoneal metastasis in gastric cancer. Oncol Rep 32:89–96CrossRef
25.
Xiong J, Han S, Ding S, He J, Zhang H (2018) Antibody-nanoparticle conjugate constructed with trastuzumab and nanoparticle albumin-bound paclitaxel for targeted therapy of human epidermal growth factor receptor 2-positive gastric cancer. Oncol Rep 39:1396–1404PubMed
26.
Awasthi N, Schwarz MA, Zhang C, Schwarz RE (2018) Augmentation of nab-paclitaxel chemotherapy response by mechanistically diverse antiangiogenic agents in preclinical gastric cancer models. Mol Cancer Ther 17:2353–2364CrossRef
27.
Zhang C-Η, Awasthi N, Schwarz MA, Schwarz RE (2013) The dual PI3 K/mTOR inhibitor NVP-BEZ235 enhances nab-paclitaxel antitumor response in experimental gastric cancer. Int J Oncol 43:1627–1635CrossRef
28.
Sasaki Y et al (2014) Phase II trial of nanoparticle albumin-bound paclitaxel as second-line chemotherapy for unresectable or recurrent gastric cancer. Cancer Sci 105:812–817CrossRef
29.
Bando H et al (2018) A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer. Eur J Cancer 91:86–91CrossRef
30.
Katsaounis P et al (2017) Nab-paclitaxel as second-line treatment in advanced gastric cancer: a multicenter phase II study of the hellenic oncology research group. Ann Gastroenterol 31:65–70PubMedPubMedCentral
31.
Kanazawa Y et al (2017) Initial experience with nab-paclitaxel for patients with advanced gastric cancer: safety and efficacy. Anticancer Res 37:2715–2720CrossRef
32.
Fukuchi M et al (2016) Efficacy of nab-paclitaxel as second-line chemotherapy for unresectable or recurrent gastric cancer. Anticancer Res 36:6699–6703CrossRef
33.
Sato S et al (2018) A phase II study of tri-weekly low-dose nab-paclitaxel chemotherapy for patients with advanced gastric cancer. Anticancer Res 38:6911–6917CrossRef
34.
Watson S et al (2019) Oxaliplatin, 5-fluorouracil and nab-paclitaxel as perioperative regimen in patients with resectable gastric adenocarcinoma: a GERCOR phase II study (FOXAGAST). Eur J Cancer 107:46–52CrossRef
35.
Shitara K et al (2017) Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial. Lancet Gastroenterol Hepatol 2:277–287CrossRef
36.
Takashima A et al (2019) Peritoneal metastasis as a predictive factor for nab-paclitaxel in patients with pretreated advanced gastric cancer: an exploratory analysis of the phase III ABSOLUTE trial. Gastric Cancer 22:155–163CrossRef
37.
Nakayama N et al (2017) A phase I study of S-1 in combination with nab-paclitaxel in patients with unresectable or recurrent gastric cancer. Gastric Cancer 20:350–357CrossRef
38.
Kawamoto Y et al (2017) Study protocol of HGCSG1404 SNOW study: a phase I/II trial of combined chemotherapy of S-1, nab-paclitaxel and oxaliplatin administered biweekly to patients with advanced gastric cancer. BMC Cancer 17:837CrossRef
39.
Gradishar W, Tjulandin S, Davidson N et al (2005) Phase III trial of nanaoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23:7794–7803CrossRef
40.
Socinski MA, Bondarenko I, Karaseva NA et al (2012) Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol 30(17):2055–2062CrossRef
41.
Goldstein D, El-Maraghi RH, Hammel P et al (2015) nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. J Natl Cancer Inst 31(2):107
Metadata
Title
Nanoparticle albumin-bound paclitaxel: a big nano for the treatment of gastric cancer
Authors
G. Roviello
F. U. Conter
E. Mini
D. Generali
M. Traversini
D. Lavacchi
S. Nobili
N. Sobhani
Publication date
01-10-2019
Publisher
Springer Berlin Heidelberg
Published in
Cancer Chemotherapy and Pharmacology / Issue 4/2019
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-019-03887-2

Other articles of this Issue 4/2019

Cancer Chemotherapy and Pharmacology 4/2019 Go to the issue

Original Article

A simple ex vivo bioassay for 5-FU transport into healthy buccal mucosal cells

Review Article

Resistance mechanisms and potent-targeted therapies of ROS1-positive lung cancer

Original Article

Pharmacokinetics and safety of erlotinib and its metabolite OSI-420 in infants and children with primary brain tumors

Original Article

Pharmacokinetics of thiotepa in high-dose regimens for autologous hematopoietic stem cell transplant in Japanese patients with pediatric tumors or adult lymphoma

Original Article

Population pharmacokinetics of trabectedin in adolescent patients with cancer

Original Article

Identification of pharmacodynamic biomarkers and common molecular mechanisms of response to genotoxic agents in cancer cell lines
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits